Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05403827 · ClinicalTrials.gov registry record · Phase 3
A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease
A Phase 3 study, sponsored by Kowa Research Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 644
- Enrollment target
NCT05403827 is a Phase 3 study that has completed, run by Kowa Research Institute. The registered enrollment target is 644 participants.
The verdict
NCT05403827, a Phase 3 study, has completed, sponsored by Kowa Research Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 644 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of K-161 ophthalmic solution for the treatment of moderate to severe dry eye disease.
Interventions
- DRUG Placebo
- DRUG K-161
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 644 participants |
| Start Date | 2022-07-03 |
| Est. Completion | 2023-12-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05403827
The ClinicalTrials.gov registry entry for NCT05403827 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 644 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kowa Research Institute, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05403827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05403827 about?
NCT05403827 is a clinical study titled "A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease". The purpose of this study is to assess the efficacy and safety of K-161 ophthalmic solution for the treatment of moderate to severe dry eye disease.
What is the current status of trial NCT05403827?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 644 participants. The study started on 2022-07-03. Estimated completion is 2023-12-05.
What interventions are being tested in trial NCT05403827?
The interventions under investigation include: Placebo (DRUG), K-161 (DRUG).
Who is sponsoring clinical trial NCT05403827?
This trial is sponsored by Kowa Research Institute, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.